Drug
Ioversol
Ioversol is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
33%
Ph early_phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (50.0%)
Phase 41 (50.0%)
Trials by Status
withdrawn133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completed
Low-acid Contrast Media for Preventing Post ERCP Pancreatitis
NCT07391787
withdrawnphase_4
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NCT03631771
completedearly_phase_1
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
NCT02117115
Clinical Trials (3)
Showing 3 of 3 trials
NCT07391787
Low-acid Contrast Media for Preventing Post ERCP Pancreatitis
NCT03631771Phase 4
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NCT02117115Early Phase 1
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3